Catalyst OrthoScience Inc. has launched the Catalyst Fracture Shoulder System, the latest innovation in its expanding product portfolio.

“At Catalyst, we’re not bound by convention—we’re defining what comes next,” Catalyst President/CEO Carl O’Connell said. “Our technology is designed to solve real shoulder arthroplasty challenges, and our clinical outcomes prove the value of that approach. We’re committed to helping shoulder surgeons achieve better results with less complexity.”

The Fracture Shoulder System’s release expands Catalyst’s differentiated portfolio, bringing a fracture-specific solution that prioritizes tuberosity fixation and healing—key factors consistently shown to produce better outcomes. Designed to improve reverse shoulder arthroplasty for proximal humeral fractures (PHFs), the system includes patented technology that helps reduce surgical complexity and drive clinical confidence. Entering a fracture market estimated at more than $250 million, Catalyst is seeing strong early adoption and is positioned to capture significant market share.

This new product release follows the recent announcement of five- to eight-year published midterm data supporting the Catalyst CSR Total Shoulder System—the first product Catalyst launched to the market. Catalyst continues to provide solutions that enable surgeons to deliver outcomes that outpace traditional total shoulder arthroplasty (TSA) solutions and this independent study introduced a new industry benchmark, showing that:

Patients who underwent anatomic total shoulder arthroplasty (aTSA) with the Catalyst CSR system experienced exceptionally high patient satisfaction, little to no pain, significant functional improvements, and very low revision rates that are well below the average data published for similar aTSA implants. 

These clinical results highlight Catalyst’s focus on anatomic precision and reproducible solutions that eliminate unnecessary complexity while enabling optimized outcomes. 

“The data speaks volumes, but so does the growing enthusiasm we’re seeing from the orthopedic community,” orthopedic surgeon Dr. Theodore Blaine stated. “Catalyst has earned a reputation for smart shoulder arthroplasty solutions that align with how surgeons work and the results they expect—whether in hospitals or ASCs—and that’s what makes it different.”

In addition to growing interest and presence at major orthopedic meetings, the company is strengthening its partnership with the American Shoulder and Elbow Surgeons (ASES) through sponsorship of the 2025 ASES Annual Meeting and the 2026 ASES Mentor & Mentee Meeting.

Based in Naples, Fla., Catalyst OrthoScience is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Its total shoulder systems are engineered for precision and efficiency, preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the United States.